Form 4: Cytokinetics Director John T. Henderson Acquires Shares in Lieu of Cash Retainer

Director John T. Henderson acquired 551 shares of Cytokinetics Inc. common stock at $38.56 per share in lieu of a cash retainer.

Summary

• On April 15, 2025, John T. Henderson, a director of Cytokinetics Inc., acquired 551 shares of common stock.
• The shares were acquired at a price of $38.56 per share.
• This acquisition was made through the Director Stock in lieu of Cash Retainer Program.
• Following the transaction, Henderson directly owns 66,348 shares and indirectly owns 83 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The director taking stock in lieu of cash is a mildly positive signal.

Positives

• The director's participation in the stock retainer program demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Cytokinetics, Director, Henderson, Stock Acquisition, Form 4, Insider Trading, Beneficial Ownership, Equity Securities